학술논문

ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC.
Document Type
Article
Source
Science Translational Medicine; 6/17/2020, Vol. 12 Issue 548, p1-10, 10p
Subject
TRANSITIONAL cell carcinoma
IMMUNE response
TUMOR markers
BLADDER cancer
BIOMARKERS
BIOLOGICAL tags
PHARMACOGENOMICS
PROGRAMMED cell death 1 receptors
Language
ISSN
19466234
Abstract
Copyright of Science Translational Medicine is the property of American Association for the Advancement of Science and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)